Despite the fact that objective response rates to 5-FU are as low as 20%, 5-FU remains the most commonly used drug for the treatment of colorectal cancer. The lack of understanding of resistance to 5-FU, therefore, remains a significant impediment in maximizing its efficacy. We used intestinal epithelial cells with an inducible K-RasV12 to demonstrate that expression of oncogenic Ras promotes cell death upon 5-FU treatment. Accordingly, transient expression of the mutant RasV12, but not the WT Ras, enhanced 5-FU-induced apoptosis in 293T cells. Consistent with these data, we showed that targeted deletion of the mutant Ras allele in the HCT116 colon cancer cell line protected cells from 5-FU-induced apoptosis. Using isogenic colon cancer cell lines that differ only by the presence of the mutant Ras allele, HCT116 and Hke-3 cells, we demonstrated that signaling by oncogenic Ras promotes both accumulation of p53 and its phosphorylation on serine15 in response to 5-FU, a situation that favors apoptosis over growth arrest. However, despite the differential induction of p53 in HCT116 and Hke-3 cells, the expression of Puma, a gene with an important role in p53-dependent apoptosis, was not affected by Ras signaling. In contrast, we showed that Ras interferes with 5-FU-induced expression of gelsolin, a protein with known antiapoptotic activity. We ascertained the role of gelsolin in 5-FU-induced apoptosis by demonstrating that silencing of gelsolin expression through RNAi sensitized cells to 5-FU-induced apoptosis and that re-expression of gelsolin in cells harboring mutant Ras protected cells from 5-FUinduced apoptosis. These data therefore demonstrate that Ras mutations increase sensitivity to 5-FU-induced apoptosis at least in part through the negative regulation of gelsolin expression. Our data indicate that Ras mutations promote apoptosis in response to 5-FU treatment and imply that tumors with Ras mutations and/or reduced expression of gelsolin may show enhanced apoptosis in response to 5-FU also in vivo.
Despite the fact that objective response rates to 5-FU are as low as 20%, 5-FU remains the most commonly used drug for the treatment of colorectal cancer. The lack of understanding of resistance to 5-FU, therefore, remains a significant impediment in maximizing its efficacy. We used intestinal epithelial cells with an inducible K-RasV12 to demonstrate that expression of oncogenic Ras promotes cell death upon 5-FU treatment. Accordingly, transient expression of the mutant RasV12, but not the WT Ras, enhanced 5-FU-induced apoptosis in 293T cells. Consistent with these data, we showed that targeted deletion of the mutant Ras allele in the HCT116 colon cancer cell line protected cells from 5-FU-induced apoptosis. Using isogenic colon cancer cell lines that differ only by the presence of the mutant Ras allele, HCT116 and Hke-3 cells, we demonstrated that signaling by oncogenic Ras promotes both accumulation of p53 and its phosphorylation on serine15 in response to 5-FU, a situation that favors apoptosis over growth arrest. However, despite the differential induction of p53 in HCT116 and Hke-3 cells, the expression of Puma, a gene with an important role in p53-dependent apoptosis, was not affected by Ras signaling. In contrast, we showed that Ras interferes with 5-FU-induced expression of gelsolin, a protein with known antiapoptotic activity. We ascertained the role of gelsolin in 5-FU-induced apoptosis by demonstrating that silencing of gelsolin expression through RNAi sensitized cells to 5-FU-induced apoptosis and that re-expression of gelsolin in cells harboring mutant Ras protected cells from 5-FUinduced apoptosis. These data therefore demonstrate thatIntroduction 5-FU is an antimetabolite that is used as a chemotherapeutic agent for a wide variety of cancers, including colorectal cancer. Its mechanism of action includes inhibition of thymidylate synthase (TS), incorporation of its metabolites into RNA and DNA, and induction of cell cycle arrest and apoptosis (reviewed in Longley et al., 2003) .
However, the overall response rates for 5-FU in colon cancer patients remain as low as 10-20% (Jones et al., 1995; Marsoni, 1995) . Different strategies have been designed to increase the antitumor activity of 5-FU, such as combining 5-FU with leucovorin, methotrexate or interferons (Benz et al., 1982; Bertino et al., 1983; Nadal et al., 1988; Greco et al., 1996; Seymour et al., 1996; Wolmark et al., 1998) , but have yielded marginal and sometimes inconclusive results. Several biomarkers have been shown to predict responsiveness of patients to 5-FU, such as TS, thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), p53, c-Myc, and microsatellite instability (reviewed in Longley et al., 2003) . We earlier demonstrated that patients whose tumors carry both amplification of c-Myc and wt p53 are more likely to respond to 5-FU (Arango et al., 2001; Augenlicht et al., 1997) and have also identified potential biomarkers of 5-FU sensitivity using cDNA microarray technology .
Oncogenic activation of Ras is present in B30-50% of colorectal cancers (Andreyev et al., 1998) ; however, its role in tumor initiation and progression remains to be determined. Several clinical studies have been conducted to examine the predictive significance of Ras mutations in colorectal cancer, but have yielded inconclusive results (Markowitz et al., 1995; Ahnen et al., 1998) . In a relatively large study of 430 patients, nonaspartate mutations of k-Ras have been shown to be associated with a significant survival benefit from combined chemotherapy, comprised of 5-FU þ levamisole or 5-FU þ leucovorin (Gnanasampanthan et al., 2001) .
A report suggested that colon cancer cell lines with mutant Ras tend to arrest at higher concentrations of 5-FU than cells with WT Ras (Huang et al., 2000) . However, another study found just the opposite -that colon cancer cell lines containing Ras mutations (SW480, HCT116, Lovo) are more sensitive to 5-FU treatment than cells with WT Ras, such as HT29 (Agarwal et al., 1999) . A drawback with both studies is that the colon cancer cell lines used differ not only by the presence of the mutant Ras but also have different genetic background. To focus on the effect of oncogenic Ras, we used rat intestinal epithelial cells with inducible expression of RasV12 (Sheng et al., 2001) , and HCT116 colon cancer cell line and its derivative with a targeted deletion of mutant Ras, Hke-3 cells (Shirasawa et al., 1993) . Both approaches led us to conclude that signaling by Ras promotes 5-FU-induced apoptosis.
We earlier used HCT116 and Hke-3 isogenic cell lines to identify Ras target genes. We performed a genomewide analysis of gene expression in these cell lines and demonstrated that several genes that promote apoptosis were upregulated by oncogenic Ras, and that genes with antiapoptotic activity were downregulated in cells that harbor activated Ras (Klampfer et al., 2004) . The proapoptotic activity of Ras is likely to contribute to the fact that oncogenic activation of Ras in normal colonic epithelial cells can lead to development of selflimiting aberrant crypt foci (ACF) that do not progress to malignancies (Pretlow, 1995) , and that in rare occasions Ras can also function as a tumor suppressor (Zhang et al., 2001) . Consistent with the proapoptotic role of Ras, we showed that cells with mutant Ras displayed increased sensitivity to apoptosis induced by the dietary chemopreventive agent butyrate (Klampfer et al., 2004) .
One of the genes that was highly downregulated by mutant Ras was gelsolin, suggesting that mutations in Ras underlie frequently reduced expression of gelsolin in primary colon tumors and in colon cancer cell lines (Bertucci et al., 2004) . Gelsolin is an actin-binding/ severing protein and thereby plays a crucial role in cellular motility (Yin and Stossel, 1979) , and also regulates apoptosis through its ability to regulate the mitochondrial membrane potential and the subsequent activation of several caspases (Kothakota et al., 1997; Azuma et al., 2000; Koya et al., 2000; Kusano et al., 2000) .
In this report, we present data which demonstrate that expression of an oncogenic Ras sensitizes cells to 5-FU and that, consistently, deletion of the mutant Ras allele in the colon cancer cells offers protection from 5-FUinduced cell death. Finally, we show that silencing of gelsolin expression through small interfering RNA (siRNA) sensitized cells to 5-FU-induced apoptosis, suggesting that Ras promotes 5-FU-induced apoptosis at least in part through downregulation of gelsolin expression.
Results

Modulation of 5-FU-induced apoptosis by mutant Ras
We earlier demonstrated that activating mutations of Ras increase sensitivity of colon cancer cells to apoptosis induced by the dietary chemopreventive agent butyrate (Klampfer et al., 2004) . To determine whether activated Ras also regulates apoptosis in response to 5-FU, a chemotherapeutic agent commonly used for the treatment of colorectal cancer, we first compared the extent of 5-FU-induced apoptosis in the isogenic colon cancer cell lines that differ only by the presence of the mutant Ras allele, HCT116 cells and Hke-3 cells. Cells were treated with increasing concentrations of 5-FU (30, 50, 75, 100 and 150 mM) for 24, 48 or 72 h, and the extent of apoptosis was determined by staining with propidium iodide. The viability of cells was not affected by the treatment of cells for 24 h. However, 48 h after treatment, we observed a significant incidence of cell death in HCT116 cells that harbor mutant Ras, but not in Hke-3 cells with a deleted mutant Ras allele (Figure 1 ). This result suggested that mutant Ras sensitizes cells to 5-FU-induced apoptosis. In contrast, 5-FU-induced cell cycle arrest did not differ among the two cell lines (data not shown), demonstrating that oncogenic Ras modulates apoptosis, but not cell cycle arrest in response to 5-FU. To confirm the apoptotic nature of cell death in 5-FUtreated cells, we compared the activation of caspases in the HCT116 and Hke-3 cells. The activity of caspase-9, an upstream caspase in the apoptotic cascade, was assessed by immunoblotting using an antibody that specifically recognizes the cleaved product of caspase-9. Activation of caspase-3, an effector caspase, was evaluated by the disappearance of the full-length protein, and the cleavage of caspase substrate, PARP, was determined by immunoblotting using an antibody that specifically recognizes cleaved PARP. Consistent with increased apoptosis in HCT116 cells, we demonstrated that 5-FU activates caspase-9 in HCT116, but not in the HKe-3 cells (Figure 2a) . Accordingly, activation of caspase-3 occurred at significantly higher concentrations of 5-FU in the Hke-3 than in the HCT116 cells (Figure 2b and c). Consistent with these data, we demonstrated the cleavage of the caspase substrate, PARP, in HCT116, but not in the Hke-3 cells (Figure 2b and c) . Together, these data demonstrated that signaling by oncogenic Ras promotes 5-FU-induced apoptosis through amplification of the caspase cascade.
To verify that the acquisition of mutant Ras promotes 5-FU-induced apoptosis, we used rat intestinal cells (IEC-6) with an inducible expression of the mutant kRasV12 (Sheng et al., 2001) . The expression of kRasV12 was induced with 5 mM IPTG (Figure 3c ), and 12 h after induction cells were treated with increasing concentrations of 5-FU. While the induction of Ras significantly enhanced cell proliferation (not shown), it decreased cell survival in the presence of 5-FU ( Figure  3a and b). As shown in Figure 3b , the expression of the oncogenic Ras was sufficient to sensitize IEC-6 cells to concentrations of 5-FU as low as 1 mM.
In addition, we transiently transfected 293 T human kidney epithelial cells with an empty vector, or the expression vector coding for the WT Ras or the activated RasV12. We showed earlier that transfection of 293T cells with RasV12 induces the activation of the ERK1/ERK2 pathway (Klampfer et al., 2003) , confirming functional Ras signaling in transfected 293T cells. As shown in Figure 3d , expression of the oncogenic, but not the WT Ras, significantly enhanced apoptosis in response to 5-FU. Taken together, we have used three different approaches (transient transfection of RasV12, inducible expression of RasV12, and targeted deletion of the mutant Ras allele) to demonstrate that oncogenic Ras sensitizes cells to 5-FU-induced apoptosis.
Activation of p53 by 5-FU is enhanced in cells harboring mutant Ras
It has been shown that 5-FU-induced apoptosis requires functional p53 in vitro Bunz et al., 1999) , and that patients harboring WT p53 display improved response to 5-FU (Arango et al., 2001) . Thus, in an attempt to define the mechanism whereby oncogenic Ras regulates the responsiveness of cells to 5-FU, we first examined whether the presence of the mutant Ras affects 5-FU-induced accumulation and activation of p53. HCT116 cells, harboring mutant Ras, and Hke-3 and HKh2 cells, two subclones with a deletion of the mutant Ras allele, were treated with increasing concentrations of 5-FU and examined for the accumulation of p53 by Western blot analysis. Each of these cell lines has a WT p53 gene, and differs only by the presence or absence of a mutant k-Ras allele.
Although 5-FU stabilized p53 in all three cell lines, p53 induction by 5-FU was consistently greater, and occurred at lower concentrations of 5-FU, in HCT116 cells than in Hkh2 and Hke-3 cells (Figure 4a ). The densitometric analysis of these results, which demonstrates enhanced accumulation of p53 in HCT116 cells compared to the Hkh2 and Hke-3 cells, is presented in Figure 4b .
p53 is a transcription factor that regulates biological processes through modulation of gene expression. Activation of several of its target genes requires that p53 be phosphorylated at multiple sites (Brooks and Gu, 2003; Vousden and Lu, 2002) . We therefore examined whether Ras mutations, in addition to regulating the extent of p53 expression, also have an affect on phosphorylation of p53 in response to 5-FU. Using an antibody that recognizes p53 phosphorylated on serine 15, we demonstrated that the amount of phosphorylated p53 in response to 5-FU treatment was significantly higher in HCT116 cells compared to the Hkh2 and Hke-3 cells (Figure 4a ).
In particular, phosphorylation of p53 on several residues has been shown to be required for the expression of p53 target genes that mediate p53-dependent apoptosis, but not for the activation of target genes that mediate p53-mediated growth arrest (Bulavin et al., 1999; Oda et al., 2000) . We therefore examined whether Ras signaling regulates the induction of Puma, a p53-induced gene that has been shown to be required for p53-mediated cell death (Nakano and Vousden, 2001; Yu et al., 2003) . We compared the induction of Puma in HCT116 and HKe-3 cells that were treated with increasing concentrations of 5-FU. Despite the fact that the amount of p53 and its phosphorylation were higher in HCT116 cells, the induction of Puma by 5-FU was comparable in HCT116 and Hke-3 cells (Figure 4c ). This result demonstrated that Ras signaling does not interfere with induction of Puma, and also established that Puma does not mediate the differential responsiveness of HCT116 and Hke-3 cells to 5-FU-induced apoptosis.
Expression of gelsolin is induced by 5-FU primarily in cells harboring WT Ras
How does oncogenic Ras regulate 5-FU-induced apoptosis? We previously demonstrated that signaling by oncogenic Ras inhibits the expression of gelsolin, an antiapoptotic gene, and that silencing of gelsolin expression sensitizes cells to apoptosis induced by chemopreventive agents, such as butyrate and sulindac sulfide (Klampfer et al., 2004) . To determine whether gelsolin also plays a role in 5-FU-induced apoptosis, we first examined whether 5-FU modulates the expression of gelsolin. HCT116 and HKe-3 cells were treated with increasing concentrations of 5-FU and the expression of gelsolin was determined by immunoblotting. Consistent with our previous report, HCT116 cells had reduced basal levels of gelsolin, and treatment of cells with 5-FU induced only a modest increase in gelsolin expression in these cells, apparent only at lower concentrations of 5-FU ( Figure  5a and b) . In contrast, we demonstrated a gradual and significant increase in gelsolin expression over a range of concentrations of 5-FU in Hke-3 cells (Figure 5a and b) . Microarray profiling has recently identified gelsolin as a 5-FU target gene also in the MCF-7 breast cancer cell line (Maxwell et al., 2003) . Gelsolin has been shown to be cleaved by caspase-3 during apoptosis, generating a cleaved product that exerts proapoptotic activity (Kothakota et al., 1997) . Although we did not detect the cleaved product of gelsolin in cells treated with high concentrations of 5-FU, we cannot exclude the possibility that in the HCT116 cells, which are undergoing extensive apoptosis in response to 5-FU treatment (Figure 1) , gelsolin is cleaved, resulting in a decline in the expression of the full-length protein.
Thus, the kinetics and the extent of gelsolin induction by 5-FU appear to be significantly altered by the presence of the oncogenic Ras, suggesting that gelsolin may mediate the differential responsiveness of HCT116 and HKe-3 cells to 5-FU.
Silencing of gelsolin expression promotes 5-FU-induced apoptosis
To define the role of gelsolin in 5-FU-induced apoptosis, we first examined whether gelsolin deficiency, as it is occurs in a subset of colon cancers, modulates the responsiveness of cells to 5-FU. We have previously demonstrated that siRNA directed against the coding region of gelsolin can be used for efficient silencing of gelsolin expression in Hke-3 cells (Klampfer et al., 2004) . Hke-3 cells were mock transfected, transfected with siRNA specific for STAT1 (as a control for specificity) or siRNA directed against the coding region of gelsolin. At 24 h after transfection, cells were treated with 5-FU for 24 h and the levels of gelsolin, p53 and bax were determined by immunoblotting. As shown in Figure 6a , gsn siRNA efficiently and specifically silenced the expression of gelsolin. In contrast, the induction of p53 by 5-FU or the levels of bax were not affected by transfection. To determine the role of gelsolin in 5-FUinduced apoptosis, Hke-3 cells transfected with nonspecific siRNA or gelsolin siRNA were treated with increasing concentrations of 5-FU as indicated in Figure  6b and c. We demonstrated that gelsolin-deficient cells displayed increased sensitivity to 5-FU-induced apoptosis ( Figure 6 ). This result established that gelsolin inhibits 5-FU-induced apoptosis and strongly suggested that the lack of gelsolin accumulation in 5-FU-treated HCT116 cells ( Figure 5 ) contributes to their increased sensitivity to 5-FU-induced apoptosis.
Since gelsolin is a known regulator of caspases (Kothakota et al., 1997; Azuma et al., 2000; Koya et al., 2000) , we examined whether gelsolin deficiency modulates caspase-3 activation in response to 5-FU treatment. The activation of caspase-3 was assessed by immunofluorescence using an antibody specific for activated caspase-3. Cells were stained simultaneously with antibody against cytochrome c to monitor the release of cytochrome c from mitochondria, and with DAPI to monitor the integrity of the nuclei. Secondary antibodies were anti-rabbit-Cy3-conjugated antibody, reacting with the activated caspase-3 (red, Figure 7a ) and anti-mouse FITC-conjugated antibody recognizing cytochrome c (green, Figure 7a ). We demonstrated that Hke-3 cells transfected with gelsolin siRNA displayed both enhanced release of cytochrome c and enhanced activation of caspase-3 compared to the cells transfected with nonspecific siRNA (Figure 7a) . Accordingly, cleavage of PARP, a substrate of activated caspases, occurred at lower concentrations of 5-FU, and to a greater extent in cells with silenced gelsolin expression (Figure 7b ).
These data demonstrated that gelsolin protects cells from 5-FU-induced apoptosis through its ability to modulate the release of cytochrome c and subsequent activation of the caspase cascade.
To confirm the role of gelsolin in the responsiveness of cells to 5-FU, we overexpressed gelsolin in HCT116 cells that harbor an activating Ras mutation and thus express low levels of gelsolin. As shown in Figure 8a , we achieved significant overexpression of gelsolin protein.
To determine whether gelsolin overexpression protects cells from 5-FU-induced apoptosis, we treated HCT116 cells transfected with an empty vector and HCT116/ gelsolin cells with increasing concentrations of 5-FU as indicated (Figure 8b ). The extent of apoptosis was determined 24 and 30 h after treatment with 5-FU. As shown in Figure 8b , overexpression of gelsolin protected cells from 5-FU-induced cell death, confirming the antiapoptotic role of gelsolin.
Discussion
To define the role of oncogenic Ras in the responsiveness of colon cancer cells to 5-FU, we compared the extent of 5-FU-induced apoptosis in the HCT116 and Hke-3 colon cancer cell lines that differ only by the presence of the mutant Ras allele. We showed that targeted deletion of the mutant Ras in HCT116 cells is sufficient to protect colon cancer cells from druginduced apoptosis, and confirmed the proapoptotic role of Ras using rat intestinal epithelial cells with inducible expression of kRasV12 (Figure 3) . These data are consistent with reports which demonstrated that oncogenic H-Ras increased sensitivity to 5-FU in fibroblasts (Tseng et al., 2003) , and that a reduction of H-Ras expression in bladder carcinoma cells conferred resistance to 5-FU-induced apoptosis (Tseng et al., 2003) . We demonstrated that HCT116 cells are also more sensitive to camptothecin-induced apoptosis than the Hke-3 cells with a deleted mutant Ras alelle (not shown), suggesting that Ras signaling represents a pathway that, through modulation of various target genes, modulates the responsiveness of cells to multiple chemotherapeutic agents. Several other oncogenes, such as c-myc, E1A, E2F-1 and CDC25A have also been shown to be dual function proteins -they can induce both cell proliferation and apoptosis Gomez et al., 1997; Guo and Hay, 1999; Hueber and Evan, 1998; Kowalik et al., 1995; Mymryk et al., 1994) . Proapoptotic activity of activated oncogenes is an important mechanism for the elimination of mutant cells, and therefore contributes to the fortunate fact that cancer is a rare disease. The proapoptotic nature of oncogenes also underscores the need of tumor cells to acquire additional changes that counteract the proapoptotic activity of activated oncogenes, such as activation of BCL-2 in the case of c-Myc-induced apoptosis (Fanidi et al., 1992) . We showed that signaling by oncogenic Ras promotes p53 accumulation in response to 5-FU, a situation that has been shown to favor apoptosis over growth arrest (Yu et al., 2003) . Likewise, induction of p53 in response to camptothecin was also significantly higher in HCT116 cells, which harbor mutant Ras, than in the Hke-3 cells (not shown). In addition to the enhanced accumulation of p53, we demonstrated enhanced phosphorylation of p53 on ser 15 in response to 5-FU in HCT116 cells. p53-deficient HCT116 cells transfected with p53 that harbors an S15A mutation displayed reduced 5-FU-induced apoptosis, despite the normal stabilization of p53, induction of p21 and Mdm2. However, six mutations of p53 (S6A, S9A, S15A, S20A, S33A and S37A) were required to completely abolish 5-FU-induced apoptosis (Kaeser et al., 2004) . Surprisingly, this was not accompanied by the lack of p53 stabilization or impaired induction of the majority of known p53 target genes (Kaeser et al., 2004) . Likewise, we showed that the induction of Puma was, despite the differential activation of p53 in the isogenic cell lines, not significantly affected by Ras signaling. This suggested that there may be additional p53 target genes that mediate 5-FU-induced apoptosis.
Activation of Ras modulates the expression of several genes involved in apoptosis (Klampfer et al., 2004) . We earlier showed that oncogenic Ras interferes with the expression of gelsolin and identified the region of the gelsolin promoter that mediates negative regulation of gelsolin by the mutant Ras (Klampfer et al., 2004) .
Here, we present data which demonstrate that Ras not only interferes with the basal expression of gelsolin but also with the inducible expression of gelsolin in response to 5-FU. Although gelsolin has been shown to be induced in response to p53 activation (Kannan et al., 2001) , it is unlikely that p53 mediates the induction of gelsolin in response to 5-FU, because we showed that the induction of gelsolin is actually stronger in Hke-3 cells, which have reduced p53 levels compared to the parental HCT116 cells. We demonstrated that gelsolin deficiency significantly enhanced 5-FU-induced activation of caspase-3, and that its overexpression blunted the 5-FU-induced apoptotic response, establishing a protective role for gelsolin in 5-FU-induced apoptosis. This is consistent with reports that human gelsolin regulates mitochondrial membrane potential and caspase activation and thereby inhibits apoptosis (Azuma et al., 2000; Koya et al., 2000; Kusano et al., 2000) . Gelsolin expression is known to be reduced in colon tumors compared to the adjacent normal mucosa (Bertucci et al., 2004) . Impaired apoptosis in cells with deficient gelsolin expression is likely to affect the progression of cancer, but may also mediate the resistance of cancer cells to chemotherapy. It is noteworthy that non-small-cell lung cancer patients with high levels of gelsolin expression have a significantly poorer prognosis than patients with reduced gelsolin expression (Shieh et al., 1999) .
We recently demonstrated that overexpression of c-Myc sensitizes colon cancer cells to 5-FU-induced Ras, gelsolin and 5-FU-induced apoptosis L Klampfer et al apoptosis (Arango et al., 2001) and showed that this is likely due to the ability of c-Myc to repress p21 induction in response to p53 activation, thus favoring apoptosis over cell cycle arrest . HCT116 cells have elevated levels of c-myc compared to the Hke-3 cells due to the presence of an activated Ras, which stabilizes c-Myc ( (Shirasawa et al., 1993) , not shown). It is therefore possible that the elevated levels of c-myc in cells that harbor mutant Ras contribute to their enhanced sensitivity to 5-FU. Notably, we showed that the levels of p21 induced in response to 5-FU or camptothecin were significantly lower in HCT116 than in Hke-3 cells (data not shown), demonstrating that the induction of p21 is repressed in cells that harbor mutant Ras, possibly due to elevated levels of c-Myc in these cells.
Genetic changes, such as mutations of the tumor suppressor p53, and epigenetic changes, such as amplifications of c-Myc have been shown to modulate the responsiveness to 5-FU both in vitro and in vivo (Arango et al., 2001) . In this report, we provide evidence that another frequent mutation in colon tumors, oncogenic activation of Ras, and the subsequent inhibition of gelsolin expression, also modulate the responsiveness of cells to 5-FU in vitro, suggesting that patients that carry Ras mutations and/or have reduced levels of gelsolin may selectively benefit from therapy with 5-FU.
Materials and methods
Cell lines, reporter gene assay and transfections
The HCT116 human colon carcinoma cell line harbors an activating mutation in codon 13 of the k-Ras proto-oncogene and is WT for p53. Two isogenic clones of the HCT116 cells with a disrupted mutant k-Ras allele, Hkh2 and Hke-3, were generated by homologous recombination (Shirasawa et al., 1993) . Cells were maintained in MEM supplemented with 10% FCS and antibiotics and their viability was assessed by the MTT assay (Boeringher, Mannheim).
Rat intestinal epithelial cells (IEC-6), transfected with inducible k-Ras were a generous gift from Raymond DuBois (Sheng et al., 2001) . Cells were maintained in DMEM containing 400 mg/ml G418 and 150 mg/ml of Hygromycin B. Expression of the oncogenic Ras was induced by 5 mM IPTG.
Gelsolin expression was downregulated using a pool of four siRNAs directed against the coding region of gelsolin (Dharmacon, Lafayette, CO, USA). Cells were transiently transfected with 5-100 nM of gelsolin siRNA using the Caphosphate method as we previously described (Klampfer et al., 2004) . Immunoblotting was performed using standard procedures (Klampfer et al., 2003) . Antibodies specific for gelsolin were obtained from Sigma, and antibodies recognizing cleaved PARP, caspase-9 and caspase-3 were purchased from Cell Signaling Technology (Beverly, MA, USA).
Apoptosis
Both adherent and floating cells were collected and resuspended in hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate), and stained with propidium iodide (50 mg/ml) for 4 h at 41C. Samples were filtered through a nylon mesh (40 mm pore size) and analysed by flow cytometry. Cell cycle distribution, and the extent of apoptosis (cells with a subG1 DNA content) were analysed using the Modfit software.
Immunofluorescence
Cells were grown on chamber slides, and were either left untreated or were treated with 5-FU as indicated. Cells were fixed in ice-cold methanol-acetic acid solution (95 : 5 V/V) for 20 min at À201C. Incubation with antibodies that recognize an activated caspase-3 (Cell signaling Technology, Beverly, MA, USA) and cytochrome c (Pharmingen) was performed overnight at 41C. Slides were washed with PBS and incubated with a secondary anti-rabbit antibody, conjugated to FITC or Cy3 for 45 min at 371C. Samples were examined with a fluorescent microscope and images acquired with a SPOT CCD camera and analysed by SPOT software. 
